Persistent Perceptual Abnormalities in Psychedelic Users: New Insights from Sensory Processing Research

Persistent Perceptual Abnormalities Are Linked to Altered Sensory Processing in Psychedelic Users

Persistent perceptual abnormalities (PPAs), such as visual distortions and hallucinations, are increasingly recognized as a potential long-term effect in some users of serotonergic psychedelics (SPs) like LSD and psilocybin. A September 2026 study published via OpenAlex (W7214582333) provides direct evidence that these PPAs are associated with measurable changes in sensory processing and a heightened susceptibility to conditioned hallucinations. The study surveyed 186 naturalistic psychedelic users, assessing their history of use, experience of PPAs, and performance on a visual conditioned hallucinations (VCH) task—a laboratory paradigm where participants report seeing stimuli that are not actually present after conditioning.

Participants with a history of PPAs, especially those with early age of first use or higher cumulative doses, exhibited lower visual thresholds (indicating increased sensitivity to visual noise), higher rates and confidence of conditioned hallucinations, and impaired sensory discrimination. These findings suggest that PPAs are not merely subjective or psychological aftereffects, but are underpinned by quantifiable changes in how the brain processes sensory information.

Mechanistic Insights: Decision Precision and the Role of Perceptual Priors

The study challenges the prevailing assumption that serotonergic psychedelics primarily reduce the influence of perceptual priors—the brain's expectations about incoming sensory data. Instead, computational modeling of participants' responses revealed that only reduced decision precision, not altered prior weighting, consistently tracked both current and past PPAs and mediated the relationship between dose and PPA severity.

This means that, rather than simply weakening prior expectations, psychedelics may increase the "noisiness" of the visual system, making it more likely for ambiguous sensory input to be interpreted as meaningful percepts. In this model, priors act as templates that convert sensory noise into expected hallucinations, especially when sensory discrimination is impaired. This nuanced view aligns more closely with models of psychosis, where hallucinations can emerge from increased uncertainty in sensory processing rather than from overactive priors alone.

One non-obvious implication: clinical screening protocols may need to account for baseline sensory discrimination abilities and not just psychiatric history, as individuals with lower sensory precision could be at higher risk for persistent perceptual disturbances after psychedelic exposure.

Implications for Clinical Trials, Public Health, and Policy

The association between PPAs and early or high-dose psychedelic exposure has immediate relevance for clinical trial design, informed consent, and public health messaging. As psychedelic-assisted therapies move through late-stage trials and into broader clinical practice, regulators and sponsors must consider how to screen for PPA risk and communicate these risks transparently to participants and patients.

• Clinical Trials: Trial protocols may benefit from pre-screening for sensory discrimination thresholds and detailed histories of prior psychedelic use, especially in younger participants.
• Public Health: Messaging should clarify that persistent perceptual changes, while rare, are more likely with early or high-dose use and may reflect lasting changes in sensory processing, not just psychological factors.
• Policy: Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) may need to update risk assessment frameworks to include sensory processing metrics and not rely solely on psychiatric exclusion criteria.

This study also highlights the importance of long-term follow-up in both clinical and naturalistic psychedelic research, as some PPAs may emerge or persist well beyond the acute effects of the drug.

Risks, Limitations, and Remaining Unknowns

While the study provides robust behavioral and computational evidence linking PPAs to altered sensory processing, several limitations and open questions remain. The sample consisted of self-selected naturalistic users, which may not generalize to clinical trial populations where dosing and set/setting are controlled. The cross-sectional design cannot establish causality—whether altered sensory processing predisposes individuals to PPAs, or results from them, is still unclear.

Additionally, the study did not assess the role of comorbid psychiatric conditions, medication use, or genetic factors that could modulate risk. The mechanisms underlying the observed reduction in decision precision—whether due to neuroplastic changes, persistent receptor alterations, or psychosocial factors—remain to be elucidated. Finally, the clinical significance of these PPAs (e.g., distress, functional impairment) was not systematically measured, leaving open the question of how often these perceptual changes translate into meaningful adverse outcomes.

Looking Forward: Research and Regulatory Pathways

Future research should prioritize longitudinal designs, objective sensory testing, and integration of neuroimaging or electrophysiological measures to clarify the causal pathways between psychedelic use, sensory processing, and persistent perceptual changes. Regulatory bodies and clinical trial sponsors may need to consider incorporating sensory discrimination tasks and computational modeling into risk assessment batteries.

As the field moves toward broader therapeutic use of psychedelics, a nuanced understanding of PPAs and their mechanistic underpinnings will be essential for balancing innovation with safety. This study underscores the need for individualized risk assessment and transparent communication about both the benefits and the potential long-term perceptual risks of psychedelic use.

How we research: This article was reviewed by Dr. Alex J. Carter, PhD (Neuroscience), on 2026-10-02. Primary source: OpenAlex W7214582333.